EBIT: Income before interest and taxes.
Capricor Therapeutics, Inc. (CAPR) had EBIT of $-108.14M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-105.04M |
|
-- |
|
-- |
|
$108.14M |
|
$-108.14M |
|
$3.10M |
|
$-105.04M |
|
$-104.88M |
|
$-105.04M |
|
$-105.04M |
|
$-105.04M |
|
$-104.89M |
|
|
EBIT |
$-108.14M |
$-106.25M |
|
46.48M |
|
46.48M |
|
$-2.26 |
|
$-2.26 |
|
| Balance Sheet Financials | |
$322.94M |
|
$18.31M |
|
$33.01M |
|
$355.95M |
|
$35.84M |
|
-- |
|
$14.32M |
|
$50.16M |
|
$305.79M |
|
$305.79M |
|
$305.79M |
|
64.95M |
|
| Cash Flow Statement Financials | |
$-69.81M |
|
$97.48M |
|
$248.89M |
|
$11.29M |
|
$287.85M |
|
$276.56M |
|
$16.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$179.06M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-34.35% |
|
-34.35% |
|
-29.51% |
|
-34.35% |
|
$4.71 |
|
$3.85 |
|
$-1.50 |
|